Ping Cao is the founder of BridGene Biosciences. Latest round: Series B. Backed by Bayland Capital, GTJA Investment Group, Proxima Ventures.
Ping Cao, Ph.D., is the Co-Founder and CEO of BridGene Biosciences, a biotechnology company focused on discovering small-molecule medicines for historically hard-to-drug proteins. He leads the company's efforts in developing innovative small molecules targeting high-value, previously undruggable targets to treat diseases.
Full founder directory · Investor directory · Company funding database · Fundraising library